CLINICAL_TRIALS
trial_result
· 2026-02-27
Clinical Trial Update: RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome) [Phase 3]
Summary
Phase 3 trial RGX-121-3102 gene therapy for Mucopolysaccharidosis type II (Hunter syndrome) is currently suspended.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: REGENXBIO Inc. | Conditions: MPS II, Hunter Syndrome (MPS II) | Phase 3 | Status: SUSPENDED